Actavis Acquires Auden Mckenzie | Chemical & Engineering News
Volume 93 Issue 5 | p. 19 | Concentrates
Issue Date: February 2, 2015

Actavis Acquires Auden Mckenzie

Department: Business
Keywords: specialty pharmaceuticals, generics, M&A

Continuing its acquisition spree, Actavis will pay roughly $460 million to buy Auden Mckenzie, a generic drug firm headquartered in London. By adding about 175 generic and branded products to its portfolio, the deal puts Actavis in the lead in the U.K. generics market. Since 2012, when it merged with Watson Pharmaceuticals, Actavis has been aggressively establishing a position in specialty pharmaceuticals through a series of acquisitions. Subsequent deals included the $5 billion purchase of Warner Chilcott; $25 billion spent on Forest Laboratories; and, most recently, $66 billion paid for Allergan.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment